Table 1.
Flucloxacillin modified peptides detected in human primary hepatocytesa
| Amino acid | Peptide b | Protein accession | Protein | -10lgP | ppm | m/z |
|---|---|---|---|---|---|---|
| K50 | YK*NVVGAR | P31946/P63104 | 1433B_HUMAN|14-3-3 protein beta/Alpha/zeta/delta | 26.34 | 3.7 | 453.8625 |
| K69 | EK*GPSVDWGK | Q16851 | UGPA_HUMAN|UTP-glucose-1-phosphate uridylyltransferase | 29.04 | 8.4 | 519.2122 |
| K258 | QIAITAGCK*TTTSAVMVHCLR | P23141 | EST1_HUMAN| Liver carboxylesterase 1 | 51.07 | −47.9 | 543.6209 |
| K376 | AK*ELIPEATEK | 35.06 | −3.3 | 561.2478 | ||
| K537 | K*AVEKPPQTEHIEL | 33.26 | 15.4 | 691.3257 | ||
| K134 | DYTK*PLEHPPVK | Q8NCE0 | SEN2_HUMAN| tRNA-splicing endonuclease subunit Sen2 | 27.1 | −21.6 | 626.261 |
| R312 | PPASQNLSINPMLLLTGR*TWK | P00325 | ADH1B_HUMAN|All-trans-retinol dehydrogenase ADH1B | 30.53 | 43 | 698.3682 |
| K450 | ISGASEK*DIVHSGLAY | P00367 | DHE3_HUMAN|GDH 1 mitochondrial | 52.17 | 6.3 | 700.6391 |
| K190 | LDELRDEGK*ASSAK | P02768 | ALBU_HUMAN|Albumin | 55.07 | 2.6 | 493.7148 |
| K915 | EIGFSDK*QISK | P31327 | CPSM_HUMAN|Carbamoyl-phosphate synthase [ammonia] mitochondrial | 21.98 | −4.2 | 568.9114 |
| K120 | HFGK*EFTPPVQAAYQK | P68871 | HBB_HUMAN|Hemoglobin β | 57.92 | 0.9 | 579.0045 |
| K120 | VLAHHFGK*EFTPPVQAAYQK | 80.17 | 2.8 | 681.0695 | ||
| K120 | AHHFGK*EFTPPVQAAYQK | 78.78 | −1 | 628.0288 | ||
| K120 | VCVLAHHFGK*EFTPPVQAAYQK | 67.06 | 5 | 596.8783 | ||
| K8 | VHLTPEEK*SAV | 24.44 | −0.2 | 554.9078 | ||
| K8 | VHLTPEEK*SAVTALWGK | 67.08 | 1.6 | 773.6954 | ||
| K82 | VLGAFSDGLAHLDNLK*GTFATLSELHCDK | 62.29 | 6.7 | 717.3376 | ||
| K95 | GTFATLSELHCDK*LHVDPENFR | 59.87 | −2.1 | 760.578 | ||
| K17 | SAVTALWGK*VNVDEVGGEALGR | 66.5 | −1.4 | 894.411 | ||
| K95 | DK*LHVDPENFR | HBB_HUMAN|Hemoglobin β/HBD_HUMAN|Hemoglobin δ | 44.22 | 3.8 | 608.2529 | |
| K144 | VVAGVANALAHK*YH | 54.95 | 2 | 476.4697 | ||
| K66 | K*VLGAFSDGLAHLDNLK | P68871/P02042 | 64.91 | 1.9 | 751.0227 | |
| K90 | SALSDLHAHK*LR | P69905 | HBA_HUMAN|Hemoglobin α | 32.42 | −3.9 | 450.9587 |
| K11 | TNVK*AAWGK | 49.46 | 0.3 | 476.5371 | ||
| K11 | VLSPADKTNVK*AAWGK | 37.61 | 4.1 | 535.2562 | ||
| K56 | TYFPHFDLSHGSAQVK*GHGK | 66.3 | 2.3 | 534.0346 | ||
| K7 | VLSPADK*TNVK | 28.26 | 0.8 | 542.2484 | ||
| K99 | VDPVNFK*LLSH | 28.17 | −1.1 | 574.5914 | ||
| K16 | AAWGK*VGAHAGEYGAEALER | 91.87 | 4.3 | 624.7679 |
a
PHHs from 2 donors were treated with 1.5 mM flucloxacillin for 24 h prior to lysis; cell lysate was digested with trypsin and analyzed by LC-MS/MS.
b
Peptide sequences were determined by both manual de novo sequencing and PEAKS X pro 10.6 (Bioinformatics Solution Inc).
*
Indicates the flucloxacillin modified residue.